1 pMM-bearing mice responded well to all treatments, including DARA; type 2-bearing pMM mice showed no reduction in tumor growth after chemotherapy, but DARA treatment (LD) resulted in an almost complete elimin
A phase I clinical trial of serotherapy in patients with acute myeloid leukemia with an immuno-globulin M monoclonal antibody to CD15. Clin Cancer Res 1995;1:965–72. CAS PubMed Google Scholar Barker E, Mueller BM, Handgretinger R, et al. Effect of a chimeric anti-ganglioside GD2 ...
Development of monoclonal antibodies against cell clusters of differentiation (CD) allows targeted therapy of known present antigens in malignant lymphoid or myeloid cells. Many of these antigens play important roles in signal transduction and ion transportation inside the cell, and after antibody modula...
With a capture system for secreted proteins at hand, we established an antibody discovery workflow with primary immune cells. To determine cell survival in the hydrogel and optimal duration of antibody secretion, we isolated mouse bone marrow plasma cells (CD138+) by positive magnetic selection and...
Infection Risk in CD19 and CD20 Targeted Treatments Anti-B cell therapies have the potential to cause hypogammaglobulinemia. Although unproven, the risk theoretically may be greater with anti-CD19 than anti-CD20 treatments, given that CD19 is expressed on a wider repertoire of B cells. In the...
Downregulation of the target antigen during antibody therapy, as has been demonstrated for CD38, may contribute to development of acquired resistance.57 The presence of soluble forms of CD3858 and SLAMF711 may also affect outcome of antibody therapy. Similarly, development of anti-idiotype antibodies...
Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 111, 3439–3441 (2008). Article CAS PubMed PubMed Central Google Scholar Zohren, F. et al. The monoclonal anti-VLA-4 antibody ...
Antiviral immunity Serum therapy Monoclonal antibody Antibody engineering 1. Passive immunization with polyclonal sera Passive immunization is based on the administration of serum from convalescent/vaccinated human donors or animals to attempt to prevent or control infection [1], [2]. Whilst vaccines requ...
CD-20 depleting antibodies Rituximab is a monoclonal antibody that binds to the B-cell surface molecule CD20 causing B-cell depletion. B cell therapy in RA aimed to reduce the production of pathogenic autoantibodies. If the patients suffer from incomplete responses to one previous TNF inhibitor, ...
cells exhibited CD138 staining with a membranous as well as a cytoplasmic expression pattern, and CD26 exhibited a cytoplasmic expression pattern. Original magnification; ×200 (upper panel), ×400 (lower panel). OCs in bone marrow tissue derived from MM patient were also positive for CD26 ...